Resmed (RMD) Notes Payables (2016 - 2025)
Resmed (RMD) has disclosed Notes Payables for 11 consecutive years, with $259.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Notes Payables rose 2523.72% year-over-year to $259.9 million, compared with a TTM value of $259.9 million through Dec 2025, up 2523.72%, and an annual FY2025 reading of $9.9 million, changed 0.0% over the prior year.
- Notes Payables was $259.9 million for Q4 2025 at Resmed, roughly flat from $259.9 million in the prior quarter.
- Across five years, Notes Payables topped out at $259.9 million in Q4 2025 and bottomed at $9.9 million in Q3 2024.
- Average Notes Payables over 5 years is $35.4 million, with a median of $9.9 million recorded in 2022.
- The sharpest move saw Notes Payables dropped 17.5% in 2022, then surged 2526.3% in 2025.
- Year by year, Notes Payables stood at $12.0 million in 2021, then fell by 17.5% to $9.9 million in 2022, then fell by 0.02% to $9.9 million in 2023, then increased by 0.08% to $9.9 million in 2024, then soared by 2523.72% to $259.9 million in 2025.
- Business Quant data shows Notes Payables for RMD at $259.9 million in Q4 2025, $259.9 million in Q3 2025, and $9.9 million in Q2 2025.